Latest Global Markets News

Bio-Gene Technology Limited updates on its development of two novel insecticides, Flavocide and Qcide, highlighting regulatory progress, commercial partnerships, and a strong market outlook across multiple sectors.

Tivan Limited has made significant progress on its Speewah Fluorite Project in Western Australia, completing a major drilling phase and advancing its Feasibility Study, now scheduled for completion in February 2026. The project aims to produce acidgrade fluorspar for global markets, supported by strong joint venture partnerships and strategic financing.

Nufarm Limited has announced Rico Christensen as its new CEO, effective January 2026, succeeding Greg Hunt who will stay on as advisor until mid-2026. Christensen brings three decades of global agricultural sector expertise and a strong operational focus.

Taiton Resources has received regulatory approval to commence drilling at the Yogi prospect within its Highway Project, targeting promising mineralisation in South Australia’s Gawler Craton. The maiden drill program aims to test a significant gravity anomaly indicative of IOCG or rare earth elements.

ResMed Inc has updated the foreign exchange rate for its upcoming dividend payable to ASX CDI holders, impacting the Australian dollar amount investors will receive.

Citigroup Global Markets Australia announces a partially franked AUD 2.80 dividend for MQG CitiFirst Self-Funding Instalment MINIs, aligning key dates with MQG ordinary shares and adjusting outstanding loan amounts.

Citigroup Global Markets Australia announces a partially franked $2.80 dividend for MQG CitiFirst Self-Funding Instalments, effective with an 18 November record date and ex-dividend trading from 17 November 2025. The dividend triggers adjustments to outstanding loan amounts across multiple instalment securities.

Resonance Health has revealed ambitious growth plans at its 2025 AGM, projecting revenue to nearly quadruple by FY26 while maintaining positive EBITDA guidance. The company is broadening its global footprint and diversifying its clinical trial services across multiple therapeutic areas.

Australian Vintage reports a modest sales dip in FY25 but charts a clear path to cash flow neutrality and growth through innovation and strategic acquisitions.

NeuroScientific Biopharmaceuticals has initiated treatment of its fourth patient under the Special Access Scheme for StemSmart™, progressing towards a Phase 2 trial targeting severe Crohn’s disease.

OFX Group reported a 5.6% decline in net operating income for 1H26 amid macroeconomic challenges but showcased strong progress in its OFX 2.0 platform transition and strategic investments aimed at long-term growth.

Eden Innovations has successfully raised $4.35 million through a placement of shortfall securities, marking a key step in its financial reconstruction and global expansion plans.